The combination of brentuximab vedotin and ESHAP has had positive results when used prior to autologous stem cell transplant in patients with refractory/relapsed Hodgkin lymphoma. Here, Ramon Garcia-Sanz, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain describes how this combination resulted in high complete remission rates and increased time to treatment failure in this challenging patient group. This interview was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.